Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
709 (USA) · Dr. Novak
consented 2013-01-15
Adverse events
Mild APPLICATION SITE DERMATITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-11 (study day 28.0); relationship: PROBABLE
Moderate APPLICATION SITE DERMATITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-11 (study day 28.0); relationship: PROBABLE
Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-11 (study day 28.0); relationship: PROBABLE
Moderate APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-11 (study day 28.0); relationship: PROBABLE
Mild APPLICATION SITE VESICLES — outcome: RECOVERED/RESOLVED; onset 2013-03-26 (study day 71.0); relationship: PROBABLE
Mild DIZZINESS — outcome: RECOVERED/RESOLVED; onset 2013-03-20 (study day 65.0); relationship: POSSIBLE
Data queries
No data queries.